Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

BELYSSE GROUP Stock Impressive Jump Before The Weekend, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with BELYSSE GROUP (BELYS.BR) jumping 11.54% to €0.87 on Friday, following the last session's downward trend. BEL 20 jumped 0.09% to €4,112.91, after two successive sessions in a row of gains, on what was a somewhat up trend trading session today.

About BELYSSE GROUP

Belysse Group NV engages in the production and sale of textile floor coverings for commercial and residential applications in Europe, North America, and internationally. The company designs, manufactures, and distributes broadloom carpets and modular carpet tiles for offices and public projects. It commercializes its products under the Bentley, modulyss, arc edition, and ITC brands. The company was formerly known as Balta Group NV and changed its name to Belysse Group NV in October 2022. Belysse Group NV was founded in 1964 and is headquartered in Waregem, Belgium. Belysse Group NV is a subsidiary of LSF9 Belysse Holdco S.à r.l.

Earnings Per Share

As for profitability, BELYSSE GROUP has a trailing twelve months EPS of €-0.31.

More news about BELYSSE GROUP (BELYS.BR).

Categories

stockMarket

Tags

BELYS.BRMarket-Close NowStock PriceBELYSSE GROUPClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com